February 25, 2020 / 7:42 AM / a month ago

BRIEF-Clinigen Group Says Trading To Date In H2 Of Current Financial Year Has Been In Line With Board's Expectations

Feb 25 (Reuters) - Clinigen Group PLC:

* HY NET REVENUE 224.6 MILLION STG VERSUS 181.1 MILLION STG

* HY STATUTORY REVENUE 243.7 MILLION STG VERSUS 208.9 MILLION STG

* HY STATUTORY PROFIT BEFORE TAX 24.8 MILLION STG VERSUS 12.9 MILLION STG

* HY STATUTORY INTERIM DIVIDEND PER SHARE 2.15P

* TRADING TO DATE IN SECOND HALF OF CURRENT FINANCIAL YEAR HAS BEEN IN LINE WITH BOARD’S EXPECTATIONS

* GROUP REMAINS IN A GOOD POSITION TO DRIVE FURTHER GROWTH ACROSS ALL PARTS OF BUSINESS IN YEAR AHEAD

* GROUP’S FUTURE ORGANIC GROSS PROFIT IS TARGETED TO GROW BY AT LEAST 5% TO 10%, WITH FY20 SET TO BE AT UPPER END OF THIS GUIDANCE

* ORGANIC EBITDA GROWTH IS EXPECTED TO MARGINALLY EXCEED ORGANIC GROSS PROFIT GROWTH IN FY20 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below